Promising new leadership Lupus drug to the FDA for approval

An experimental lupus drug has just met one main objective for the verge of the first approved treatment for the disease in more than 50 years. The goal of the new drug, called Benlysta is to the body's response to lupus in an attempt to suppress the actions of a protein control, which causes hyperactivity in patients with lupus.

It is expected that the study in a clinical program called Bliss-76 were confirmed positive results of a preliminary study last minute. Currently, information on the Bliss-76 data, a dose of 10 mg Benlysta together with steroid treatment led to an improvement of 43 percent of lupus patients held a higher dose and only 40.6 percent of participants with a lower dose. Compare with the improvements to simply 33.8 percent of patients receiving a sop.

Manufacturers of drugs, Human Genome Sciences (HGS), based in Rockville, Maryland, and GlaxoSmithKline, based in the UK, which now plans to seek regulatory approval from the Food and Drug Administration of the United States in spring 2010. If approved, could Benlysta be commercially available next year too late.

In a statement, HGS's president and CEO H. Thomas Watkins said: "The Bliss-76 results confirm our view that Benlysta has the potential, the first new drug in recent decades for people with lupus approved." He added: "We are very proud of innovation and scientific rigor, the Benlysta to this point."

Bliss-76 the 865-trial was the second of two late-stage studies are concerned, and patients treated and observed for a period of one year. In October this year, the late phase of the first study, called Bliss-52 involved more than 800 patients from Asia, South America and Eastern Europe and has proven itself to reach several key goals.

Lupus is an inflammatory disease, an autoimmune disease where the immune system attacks the body's own tissues of the body of pathogens to health problems such as rashes, mouth ulcers, and arthritis and kidney damage due to other problems. Because the disease manifests itself differently in each patient, it is difficult to develop effective therapies against the disease. According to Watkins: "We are inflicted with the option to standard of trouble pro patients with lupus must be redefined."

Although a recent study estimates that 322,000 Americans, probably the most common form of the disease such as lupus erythematosus, Lupus Foundation of America estimates that about 1.5 million Americans suffer from some form of the disease are known. According to Sandra C. Raymond, president and CEO of the organization maintained "people with lupus and their families have more than 50 years that it is possible to develop therapies for diseases control." She continued: "We believe it is an important first step in the development of the whole arsenal of therapies and lupus requires individual treatment.